TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.
Follow-Up Questions
Who is the CEO of TC Biopharm (Holdings) PLC?
Mr. Bryan Kobel is the Chief Executive Officer of TC Biopharm (Holdings) PLC, joining the firm since 2021.
What is the price performance of TCBPY stock?
The current price of TCBPY is $0.28, it has decreased 0% in the last trading day.
What are the primary business themes or industries for TC Biopharm (Holdings) PLC?
TC Biopharm (Holdings) PLC belongs to Biotechnology industry and the sector is Health Care
What is TC Biopharm (Holdings) PLC market cap?
TC Biopharm (Holdings) PLC's current market cap is $2.8M
Is TC Biopharm (Holdings) PLC a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for TC Biopharm (Holdings) PLC, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell
